{"id":"W2129448596","doi":"10.1016/j.neurobiolaging.2015.09.018","title":"MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials","year":2015,"lang":"en","type":"article","venue":"Neurobiology of Aging","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; University of California; National Institutes of Health; Genentech; IXICO; Servier; Eisai; Northern California Institute for Research and Education; University of California, San Diego; DoD Alzheimer's Disease Neuroimaging Initiative; Pfizer; Biogen; BioClinica; F. Hoffmann-La Roche; Synarc; University of Southern California; Medpace; U.S. Department of Defense; Eli Lilly and Company; Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Alzheimer's Disease Neuroimaging Initiative; Meso Scale Diagnostics; Alzheimer's Association","keywords":"Neuroimaging; Magnetic resonance imaging; Atrophy; Cohort; Medicine; Statistical power; Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; Positron emission tomography; Biomarker; Clinical trial; Sample size determination; Nuclear medicine; Internal medicine; Psychology; Disease; Radiology; Psychiatry; Statistics; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001286258,0.00008873106,0.0004185928,0.0001185905,0.00004084007,0.00001009714,0.0000215874,0.00006203869,0.00001962292],"category_scores_gemma":[0.001999652,0.00006963414,0.00008067083,0.00005586473,0.0001273114,0.00004442181,0.00001560489,0.00009381472,0.000002545124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001837883,"about_ca_system_score_gemma":0.0003073571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001256001,"about_ca_topic_score_gemma":0.000008139308,"domain_scores_codex":[0.9984799,0.0005860733,0.0004859762,0.0002249489,0.00006245888,0.0001606585],"domain_scores_gemma":[0.9968503,0.002634001,0.0001226015,0.00011592,0.0001144982,0.0001627235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008702141,0.005879383,0.9344252,0.0002307432,0.00364876,0.0002310293,0.0004433779,0.00016551,0.01138464,0.0008331569,0.02554964,0.008506388],"study_design_scores_gemma":[0.3605327,0.04226745,0.415055,0.0005540647,0.003275671,0.0001345245,0.0006692287,0.01961691,0.1430063,0.01170108,0.002156363,0.001030688],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898343,0.001141978,0.0002167629,0.007593868,0.00009356152,0.00101735,0.00004567417,0.00001561925,0.00004087996],"genre_scores_gemma":[0.9971888,0.00006934657,0.001527895,0.0009401247,0.00007722875,0.00006825246,0.0001148489,0.000007699291,0.000005779752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5193702,"threshold_uncertainty_score":0.2839598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3361830784574369,"score_gpt":0.521550541137829,"score_spread":0.1853674626803921,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}